Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy

IOVA announced promising initial data from a cohort — Cohort 3B — of its ongoing phase II basket study, IOV-COM-202, evaluating single administration of its tumor infiltrating lymphocyte (TIL) therapy candidate, LN-145, in patients with metastatic non-small cell lung cancer (mNSCLC).